Company intelligence / Profile preview
Tasly Biopharmaceuticals Co., Ltd.
Tianjin, Tianjin, Chinaen.taslypharma.com ↗
- Ownership
- Private
- Employees
- ~10958
- Development stage
- Other
01
Overview
Tasly has multiple products in various clinical stages, including completed Phase III trials for T89 for chronic stable angina, ongoing Phase II studies for TSL1502 for various cancers, and completed Phase I trials for UMSC01 for acute myocardial infarction and ischemic stroke.
- Therapeutic areas
- OncologyPulmonologyMetabolic DisordersCardiovascularNeurologyInfectious Diseases
- Modalities
- Small MoleculesBiologicsHerbal/Traditional Chinese MedicineStem CellsPolypeptides
- Industry
- Pharma
02
Drug pipeline
1 asset03
Partnerships
Sutro BiopharmaHerbalifeHuawei Cloud Computing Technology Co
Beyond the preview
Go deeper on Tasly Biopharmaceuticals Co., Ltd..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Tasly Biopharmaceuticals Co., Ltd..